Rheumatoid arthritis (RA) affects roughly 18 million people worldwide, making it one of the most common autoimmune diseases on the planet. In the United States alone, an estimated 10.6 million adults have been diagnosed with it, representing about 4.1% of the adult population. While it’s far less common than osteoarthritis, RA is not rare, and its prevalence has been steadily climbing for three decades.
U.S. and Global Numbers
Among all types of arthritis diagnosed in American adults, RA accounts for about 15.8% of cases. Osteoarthritis is the most common form, affecting roughly 33 million people, but RA’s 10.6 million cases make it the second most prevalent subtype. Globally, the age-standardized incidence rate rose from about 10.4 per 100,000 people in 1990 to 11.8 per 100,000 in 2021. That translates to a roughly half-percent annual increase in new cases each year over three decades. The encouraging counterpoint: mortality from RA has declined significantly over the same period, dropping nearly 1.7% per year, likely due to better treatment options.
Who Gets RA Most Often
Women develop RA at roughly three times the rate of men. This gap is one of the most consistent findings across populations worldwide, though the exact ratio varies by region. Hormonal differences, particularly fluctuations in estrogen, are thought to play a central role in this disparity.
Most people develop RA between the ages of 30 and 60. It can appear earlier, and when symptoms begin after age 60, clinicians refer to it as later-onset rheumatoid arthritis. Children can also develop inflammatory arthritis. An estimated 220,000 U.S. children and adolescents under 18 have been diagnosed with some form of arthritis, though the childhood forms (grouped under juvenile idiopathic arthritis) are classified differently from adult RA. Prevalence in children increases with age, rising from 77 per 100,000 in kids under 6 to 592 per 100,000 in those aged 12 to 17.
Risk Factors That Shift the Odds
Genetics load the gun, but environment pulls the trigger. Having a family history of RA increases your risk, and certain gene variants involved in immune function make the disease more likely. But modifiable factors matter too.
Smoking is one of the strongest environmental risk factors. In people who already carry genetic or immune markers that put them at risk, a history of smoking combined with being overweight pushed the likelihood of developing arthritis to 60% over a roughly two-year follow-up period, compared to an overall risk of 28% in the broader at-risk group. Smoking appears to trigger the specific type of immune response that attacks joint tissue in RA, and the risk doesn’t fully disappear after quitting.
Obesity adds to the problem on its own, both by increasing systemic inflammation and by altering immune function. Data on children hints at a similar pattern: arthritis prevalence was higher among kids with overweight (1,040 per 100,000) compared to those without, and higher in households with smokers (560 per 100,000) versus smoke-free homes (260 per 100,000).
How RA Is Diagnosed
There’s no single test that confirms RA. Diagnosis relies on a combination of findings. A doctor needs to identify active joint swelling (not just pain) in at least one joint that isn’t better explained by another condition. From there, a scoring system considers four factors: how many joints are involved and which ones, whether blood tests show specific immune markers, whether inflammation markers are elevated, and how long symptoms have lasted. A score of 6 out of 10 or higher on this system points to a definitive diagnosis.
This scoring approach, introduced in 2010, was designed to catch RA earlier than older criteria allowed. Earlier diagnosis matters because joint damage in RA begins quickly, sometimes within months of symptom onset, and treatment started early tends to preserve more joint function over time.
The Financial Weight of RA
RA is expensive to manage. The average annual healthcare cost for an RA patient in the United States reached $17,800 in 2018, a 37% increase over the prior decade. Much of this is driven by the biologic medications that have transformed RA treatment but come with high price tags. Out-of-pocket costs for prescriptions averaged $574 per year, with additional costs for office visits and other care adding to the burden. These costs can compound over decades, since RA is a lifelong condition typically diagnosed during prime working years.
Why Numbers Are Rising
The steady global increase in RA cases over the past 30 years likely reflects several overlapping trends. Populations are aging, and older adults are more likely to develop RA. Rising obesity rates worldwide increase the pool of people with chronic low-grade inflammation. Better diagnostic tools and earlier screening catch cases that might have gone unrecognized in previous decades. And in some regions, higher smoking rates among women may contribute to closing the gap between observed and actual prevalence. Whatever the mix of causes, RA is not becoming less common. The global burden continues to grow even as outcomes for individual patients improve.